With the FDA’s approval of lecanemab, Eisai is set to promote it to the primary care physicians who treat most dementia patients and critics are speaking out.
Overcoming the pain of change
CHAP answers agencies' questions regarding post-PHE waivers and flexibilities
Take control of your incontinence business
Estrella talks HME, staying positive and never backing down
HomeCare talked with Knowlton to find out more about the results and the latest in interoperability.
